PURPOSE: Acute and late changes in magnetic resonance imaging of the pediatric brain have been described after radiotherapy (RT). We report the post-RT neuroimaging changes in the posterior fossa after intensity-modulated RT (IMRT) in children with medulloblastoma and contrast them with those of leptomeningeal disease. METHODS AND MATERIALS: We performed a retrospective review of 53 consecutive children with medulloblastoma who were treated with craniospinal RT followed by IMRT to the posterior fossa and chemotherapy between 1997 and 2006. RESULTS: After IMRT to the posterior fossa, 8 (15%) of 53 patients developed increased fluid-attenuated inversion-recovery signal changes in the brainstem or cerebellum and patchy, multifocal, nodular contrast enhancement at a median of 6 months. The enhancement superficially resembled leptomeningeal disease. However, the enhancement resolved without intervention at a median of 6 months later. The accompanying fluid-attenuated inversion-recovery signal changes occasionally preceded the enhancement, were often parenchymal in location, and resolved or persisted to a lesser degree. All 8 patients with transient magnetic resonance imaging changes in the posterior fossa were alive at last follow-up. In contrast, leptomeningeal disease occurred in 8 (15%) of our 53 patients at a median of 19.5 months after IMRT completion. Of these 8 patients, 7 demonstrated initial nodular enhancement outside the conformal field, and 7 patients died. CONCLUSION: Magnetic resonance imaging changes can occur in the posterior fossa of children treated with IMRT for medulloblastoma. In our experience, these transient changes occur at a characteristic time and location after RT, allowing them to be distinguished from leptomeningeal disease.
PURPOSE: Acute and late changes in magnetic resonance imaging of the pediatric brain have been described after radiotherapy (RT). We report the post-RT neuroimaging changes in the posterior fossa after intensity-modulated RT (IMRT) in children with medulloblastoma and contrast them with those of leptomeningeal disease. METHODS AND MATERIALS: We performed a retrospective review of 53 consecutive children with medulloblastoma who were treated with craniospinal RT followed by IMRT to the posterior fossa and chemotherapy between 1997 and 2006. RESULTS: After IMRT to the posterior fossa, 8 (15%) of 53 patients developed increased fluid-attenuated inversion-recovery signal changes in the brainstem or cerebellum and patchy, multifocal, nodular contrast enhancement at a median of 6 months. The enhancement superficially resembled leptomeningeal disease. However, the enhancement resolved without intervention at a median of 6 months later. The accompanying fluid-attenuated inversion-recovery signal changes occasionally preceded the enhancement, were often parenchymal in location, and resolved or persisted to a lesser degree. All 8 patients with transient magnetic resonance imaging changes in the posterior fossa were alive at last follow-up. In contrast, leptomeningeal disease occurred in 8 (15%) of our 53 patients at a median of 19.5 months after IMRT completion. Of these 8 patients, 7 demonstrated initial nodular enhancement outside the conformal field, and 7 patients died. CONCLUSION: Magnetic resonance imaging changes can occur in the posterior fossa of children treated with IMRT for medulloblastoma. In our experience, these transient changes occur at a characteristic time and location after RT, allowing them to be distinguished from leptomeningeal disease.
Authors: W E Reddick; J M Russell; J O Glass; X Xiong; R K Mulhern; J W Langston; T E Merchant; L E Kun; A Gajjar Journal: Magn Reson Imaging Date: 2000-09 Impact factor: 2.546
Authors: Kathleen J Helton; Michael Edwards; R Grant Steen; Thomas E Merchant; Mark V Sapp; Frederick A Boop; James Langston Journal: J Neurosurg Date: 2005-03 Impact factor: 5.115
Authors: D M Ashley; L Meier; T Kerby; F M Zalduondo; H S Friedman; A Gajjar; L Kun; P K Duffner; S Smith; D Longee Journal: J Clin Oncol Date: 1996-06 Impact factor: 44.544
Authors: Amar Gajjar; Murali Chintagumpala; David Ashley; Stewart Kellie; Larry E Kun; Thomas E Merchant; Shaio Woo; Greg Wheeler; Valerie Ahern; Matthew J Krasin; Maryam Fouladi; Alberto Broniscer; Robert Krance; Gregory A Hale; Clinton F Stewart; Robert Dauser; Robert A Sanford; Christine Fuller; Ching Lau; James M Boyett; Dana Wallace; Richard J Gilbertson Journal: Lancet Oncol Date: 2006-10 Impact factor: 41.316
Authors: W M Wara; Q T Le; P K Sneed; D A Larson; M D Prados; V A Levin; M S Edwards; M D Weil Journal: Int J Radiat Oncol Biol Phys Date: 1994-10-15 Impact factor: 7.038
Authors: I J Dunkel; J M Boyett; A Yates; M Rosenblum; J H Garvin; B C Bostrom; S Goldman; L S Sender; S L Gardner; H Li; J C Allen; J L Finlay Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: E Bouffet; F Doz; M C Demaille; P Tron; H Roche; D Plantaz; A Thyss; J L Stephan; O Lejars; E Sariban; M Buclon; J M Zücker; M Brunat-Mentigny; J L Bernard; J C Gentet Journal: Br J Cancer Date: 1998-04 Impact factor: 7.640
Authors: N D Sabin; T E Merchant; J H Harreld; Z Patay; P Klimo; I Qaddoumi; G T Armstrong; K Wright; J Gray; D J Indelicato; A Gajjar Journal: AJNR Am J Neuroradiol Date: 2012-07-19 Impact factor: 3.825
Authors: M Balducci; S Chiesa; D Chieffo; S Manfrida; N Dinapoli; A Fiorentino; F Miccichè; V Frascino; C Anile; V Valentini; B De Bari Journal: J Neurooncol Date: 2011-07-31 Impact factor: 4.130
Authors: V Strenger; H Lackner; R Mayer; P Sminia; P Sovinz; M Mokry; A Pilhatsch; M Benesch; W Schwinger; M Seidel; D Sperl; S Schmidt; C Urban Journal: Strahlenther Onkol Date: 2013-08-22 Impact factor: 3.621
Authors: J H Harreld; P Zou; N D Sabin; A Edwards; Y Han; Y Li; O Bieri; R B Khan; A Gajjar; G Robinson; T E Merchant Journal: AJNR Am J Neuroradiol Date: 2022-01-20 Impact factor: 3.825
Authors: Giovanni Morana; Cesar Augusto Alves; Domenico Tortora; Mariasavina Severino; Paolo Nozza; Armando Cama; Marcello Ravegnani; Gabriella D'Apolito; Alessandro Raso; Claudia Milanaccio; Claudia da Costa Leite; Maria Luisa Garrè; Andrea Rossi Journal: Oncotarget Date: 2017-07-25